Clinical trial
Phase II Trial of Pentostatin and Targeted Busulfan
NCT00496340 · H. Lee Moffitt Cancer Center and Research Institute, Other · Completed
Key facts
| NCT number | NCT00496340 |
|---|---|
| Title | Phase II Trial of Pentostatin and Targeted Busulfan |
| Official title | Phase II Trial of Pentostatin and Targeted Busulfan as a Novel Reduced Intensity Regimen for Allogeneic Hematopoietic Stem Cell Transplantation Using Laboratory-Guided (CD4-guided) Immunosuppression. |
| Acronym | Pento & tBU |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hematologic Malignancies |
| Intervention type | Drug, Procedure |
| Interventions | Pentostatin, Busulfan, Rituximab, Allogeneic Hematopoietic Cell Transplant |
| Enrollment | 42 |
| Start date | Jul 1, 2007 |
| Primary completion | Apr 1, 2013 |
| Completion | Aug 1, 2013 |
| First posted | Jul 4, 2007 |
| Last update posted | Jun 5, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: